You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDexmedetomidine
Accession NumberDB00633  (APRD00578)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionAn agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. [PubChem]
Structure
Thumb
Synonyms
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-medetomidine
(S)-medetomidine
Dexmedetomidin
Dexmedetomidina
Dexmédétomidine
Dexmedetomidinum
External Identifiers
  • MPV 1440
  • MPV 785
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dexmedetomidine HydrochlorideInjection, solution, concentrate100 ug/mLIntravenousSandoz Inc.2014-10-03Not applicableUs
Dexmedetomidine HydrochlorideInjection, solution, concentrate100 ug/mLIntravenousWG Critical Care, LLC2016-04-19Not applicableUs
Dexmedetomidine HydrochlorideInjection, solution, concentrate100 ug/mLIntravenousWG Critical Care, LLC2016-04-19Not applicableUs
PrecedexSolution4 mcgIntravenousHospira Healthcare Corporation2016-05-09Not applicableCanada
PrecedexSolution100 mcgIntravenousHospira Healthcare Corporation2010-02-24Not applicableCanada
PrecedexInjection, solution, concentrate100 ug/mLIntravenousHospira, Inc.1999-12-17Not applicableUs
PrecedexInjection, solution4 ug/mLIntravenousHospira, Inc.2013-03-13Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DexmedetomidineInjection, solution, concentrate100 ug/mLIntravenousAkorn, Inc.2014-11-24Not applicableUs
Dexmedetomidine HydrochlorideInjection, solution100 ug/mLIntravenousAccord Healthcare Inc.2016-05-13Not applicableUs
Dexmedetomidine HydrochlorideInjection, solution100 ug/mLIntravenousFresenius Kabi USA, LLC2015-09-18Not applicableUs
Dexmedetomidine HydrochlorideInjection, solution100 ug/mLIntravenousActavis Pharma, Inc.2016-10-18Not applicableUs
Dexmedetomidine HydrochlorideInjection, solution, concentrate100 ug/mLIntravenousPar Pharmaceutical, Inc.2014-08-19Not applicableUs
Dexmedetomidine HydrochlorideInjection, solution, concentrate100 ug/mLIntravenousMylan Institutional LLC2014-08-18Not applicableUs
Dexmedetomidine HydrochlorideInjection, solution, concentrate100 ug/mLIntravenousMylan Institutional LLC2015-06-092017-07-31Us
Dexmedetomidine HydrochlorideInjection, solution100 ug/mLIntravenousSun Pharmaceuticals Industries Inc.2015-04-08Not applicableUs
Dexmedetomidine HydrochlorideInjection, solution100 ug/mLIntravenousAuro Medics Pharma Llc2016-03-17Not applicableUs
Dexmedetomidine HydrochlorideInjection, solution100 ug/mLIntravenousSandoz Inc2016-11-14Not applicableUs
Dexmedetomidine HydrochlorideInjection, solution, concentrate100 ug/mLIntravenousMylan Institutional LLC2015-06-022016-10-13Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DexdorOrion
DexemThemis Medicare
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dexmedetomidine hydrochloride
ThumbNot applicableDBSALT001013
Categories
UNII67VB76HONO
CAS number113775-47-6
WeightAverage: 200.2795
Monoisotopic: 200.131348522
Chemical FormulaC13H16N2
InChI KeyCUHVIMMYOGQXCV-NSHDSACASA-N
InChI
InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1
IUPAC Name
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
SMILES
C[[email protected]](C1=CNC=N1)C1=C(C)C(C)=CC=C1
Pharmacology
IndicationFor sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief; anxiety reduction and analgesia
Structured Indications
PharmacodynamicsDexmedetomidine activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia.
Mechanism of actionDexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-2A adrenergic receptorProteinyes
agonist
HumanP08913 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 118 L
Protein binding94%
Metabolism

Hepatic

Route of eliminationA mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces. Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion. The majority of metabolites are excreted in the urine.
Half life2 hours
Clearance
  • 39 L/h [Healthy volunteers receiving IV infusion (0.2-0.7 mcg/kg/hr)]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with 7-Nitroindazole.Experimental
AcebutololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Agomelatine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexmedetomidine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dexmedetomidine.Approved, Illicit, Investigational
AlprenololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmifostineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Dexmedetomidine.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Dexmedetomidine.Illicit, Withdrawn
AmiodaroneDexmedetomidine may increase the bradycardic activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Dexmedetomidine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dexmedetomidine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amyl Nitrite.Approved
Aop200704Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Dexmedetomidine.Approved, Investigational
ArotinololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Asenapine.Approved
AtenololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Azaperone.Vet Approved
AzelastineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Azilsartan medoxomil.Approved
BaclofenThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Dexmedetomidine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Barnidipine.Approved
BefunololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Dexmedetomidine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dexmedetomidine.Approved
BenperidolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineDexmedetomidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bepridil.Approved, Withdrawn
BeractantDexmedetomidine may increase the bradycardic activities of Beractant.Approved
BetaxololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BisoprololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bortezomib.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Dexmedetomidine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dexmedetomidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bromazepam.Approved, Illicit
BromocriptineBromocriptine may increase the hypertensive activities of Dexmedetomidine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Brotizolam.Approved, Withdrawn
BucindololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexmedetomidine.Approved, Investigational
BupranololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dexmedetomidine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dexmedetomidine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dexmedetomidine.Approved, Illicit, Vet Approved
CabergolineCabergoline may increase the hypertensive activities of Dexmedetomidine.Approved
CalfactantDexmedetomidine may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Candesartan.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexmedetomidine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carisoprodol.Approved
CarteololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibDexmedetomidine may increase the bradycardic activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dexmedetomidine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexmedetomidine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dexmedetomidine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorzoxazone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cilnidipine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dexmedetomidine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with clomethiazole.Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dexmedetomidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dexmedetomidine.Approved, Illicit
ClotrimazoleThe metabolism of Dexmedetomidine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dexmedetomidine.Approved
CocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dexmedetomidine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Conivaptan.Approved, Investigational
CrizotinibDexmedetomidine may increase the bradycardic activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Dexmedetomidine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Dexmedetomidine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexmedetomidine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desflurane.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Dexmedetomidine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Dexmedetomidine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dexbrompheniramine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diclofenamide.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Difenoxin.Approved, Illicit
DigoxinDigoxin may increase the bradycardic activities of Dexmedetomidine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Dexmedetomidine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Dexmedetomidine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dipyridamole.Approved
DisulfiramThe metabolism of Dexmedetomidine can be decreased when combined with Disulfiram.Approved
DonepezilDexmedetomidine may increase the bradycardic activities of Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Doramectin.Vet Approved
DosulepinDosulepin may decrease the antihypertensive activities of Dexmedetomidine.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dexmedetomidine.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Dexmedetomidine.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Illicit
DronedaroneDexmedetomidine may increase the bradycardic activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Drotebanol.Experimental, Illicit
DuloxetineDexmedetomidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Dexmedetomidine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dexmedetomidine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Eprosartan.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Dexmedetomidine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Dexmedetomidine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Dexmedetomidine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Escitalopram.Approved, Investigational
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Dexmedetomidine.Investigational
EsmololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexmedetomidine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etacrynic acid.Approved
EthanolDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dexmedetomidine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexmedetomidine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexmedetomidine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fimasartan.Approved
FingolimodDexmedetomidine may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexmedetomidine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dexmedetomidine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dexmedetomidine.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with gabapentin enacarbil.Approved
GalantamineDexmedetomidine may increase the bradycardic activities of Galantamine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dexmedetomidine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hexobarbital.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Dexmedetomidine.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexmedetomidine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Dexmedetomidine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indapamide.Approved
IndenololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Dexmedetomidine.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Dexmedetomidine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Dexmedetomidine.Approved
IvabradineDexmedetomidine may increase the bradycardic activities of Ivabradine.Approved
KetamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketobemidone.Approved
LabetalolDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lacidipine.Approved
LacosamideDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lamotrigine.Approved, Investigational
LanreotideDexmedetomidine may increase the bradycardic activities of Lanreotide.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levocetirizine.Approved
LevodopaDexmedetomidine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Dexmedetomidine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dexmedetomidine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lofexidine.Approved, Investigational
LoratadineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dexmedetomidine.Approved
LosartanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dexmedetomidine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lu AA21004.Investigational
LucinactantDexmedetomidine may increase the bradycardic activities of Lucinactant.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dexmedetomidine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dexmedetomidine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dexmedetomidine.Approved
MethotrimeprazineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dexmedetomidine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methyldopa.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Dexmedetomidine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dexmedetomidine.Approved, Investigational
MetyrosineDexmedetomidine may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Midazolam.Approved, Illicit
MilnacipranMilnacipran may increase the tachycardic activities of Dexmedetomidine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dexmedetomidine.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Dexmedetomidine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dexmedetomidine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Investigational
NadololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nalbuphine.Approved
NebivololThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dexmedetomidine.Approved
NicorandilNicorandil may increase the hypotensive activities of Dexmedetomidine.Approved
NicotineThe metabolism of Dexmedetomidine can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dexmedetomidine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dexmedetomidine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dexmedetomidine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Dexmedetomidine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the bradycardic activities of Dexmedetomidine.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dexmedetomidine.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dexmedetomidine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ondansetron.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Dexmedetomidine.Investigational
OpiumThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Opium.Approved, Illicit
OrphenadrineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxetacaine.Investigational
OxprenololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexmedetomidine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paliperidone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Papaverine.Approved
ParaldehydeDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paroxetine.Approved, Investigational
PasireotideDexmedetomidine may increase the bradycardic activities of Pasireotide.Approved
PenbutololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dexmedetomidine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved
PerazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dexmedetomidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phenelzine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phenoxyethanol.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phentolamine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pimozide.Approved
PindololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pomalidomide.Approved
Poractant alfaDexmedetomidine may increase the bradycardic activities of Poractant alfa.Approved
PractololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleDexmedetomidine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Dexmedetomidine.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dexmedetomidine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexmedetomidine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dexmedetomidine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Promethazine.Approved
PropafenoneDexmedetomidine may increase the bradycardic activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Propoxycaine.Approved
PropranololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Dexmedetomidine.Approved
PSD502The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quinapril.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Dexmedetomidine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dexmedetomidine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dexmedetomidine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Riociguat.Approved
RisperidoneDexmedetomidine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ritanserin.Investigational
RivastigmineDexmedetomidine may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Romifidine.Vet Approved
RopiniroleDexmedetomidine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexmedetomidine.Approved
RotigotineDexmedetomidine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dexmedetomidine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Dexmedetomidine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dexmedetomidine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sevoflurane.Approved, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Dexmedetomidine.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved
SotalolDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Dexmedetomidine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Streptokinase.Approved
SufentanilDexmedetomidine may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dexmedetomidine.Approved
SuvorexantDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tasimelteon.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dexmedetomidine.Approved
TerazosinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Terazosin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetrodotoxin.Investigational
ThalidomideDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dexmedetomidine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dexmedetomidine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tiagabine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Dexmedetomidine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Dexmedetomidine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tiletamine.Vet Approved
TimololDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Dexmedetomidine.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Dexmedetomidine.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Dexmedetomidine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dexmedetomidine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dexmedetomidine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Dexmedetomidine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexmedetomidine.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Dexmedetomidine.Experimental
TrimipramineTrimipramine may decrease the antihypertensive activities of Dexmedetomidine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dexmedetomidine.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Dexmedetomidine.Approved, Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Dexmedetomidine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexmedetomidine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zolazepam.Vet Approved
ZolpidemDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Inese Reine, Armands Zandersons, “METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS..” U.S. Patent US20100048915, issued February 25, 2010.

US20100048915
General ReferencesNot Available
External Links
ATC CodesN05CM18
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (43.9 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9928
Blood Brain Barrier+0.9663
Caco-2 permeable+0.5471
P-glycoprotein substrateNon-substrate0.7118
P-glycoprotein inhibitor INon-inhibitor0.8925
P-glycoprotein inhibitor IINon-inhibitor0.9845
Renal organic cation transporterNon-inhibitor0.824
CYP450 2C9 substrateNon-substrate0.8067
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.5083
CYP450 2D6 inhibitorNon-inhibitor0.8218
CYP450 2C19 inhibitorInhibitor0.8564
CYP450 3A4 inhibitorInhibitor0.5684
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6714
Ames testNon AMES toxic0.6167
CarcinogenicityNon-carcinogens0.9178
BiodegradationNot ready biodegradable0.948
Rat acute toxicity2.4712 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9581
hERG inhibition (predictor II)Non-inhibitor0.9236
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous100 ug/mL
Injection, solution, concentrateIntravenous100 ug/mL
Injection, solutionIntravenous4 ug/mL
SolutionIntravenous100 mcg
SolutionIntravenous4 mcg
Prices
Unit descriptionCostUnit
Precedex 200 mcg/2 ml vial41.32USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1337659 No1995-11-282012-11-28Canada
CA2326339 No2008-12-232019-03-31Canada
US5344840 No1994-09-062011-09-06Us
US6716867 Yes1999-10-012019-10-01Us
US8242158 Yes2012-07-042032-07-04Us
US8338470 Yes2012-07-042032-07-04Us
US8455527 Yes2012-07-042032-07-04Us
US8648106 Yes2012-07-042032-07-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityFreely soluble in waterNot Available
logP2.8Not Available
pKa7.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.174 mg/mLALOGPS
logP3.28ALOGPS
logP3.39ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)6.54ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area28.68 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity62.98 m3·mol-1ChemAxon
Polarizability23.32 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassNot Available
Direct ParentBenzene and substituted derivatives
Alternative Parents
Substituents
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Fairbanks CA, Stone LS, Kitto KF, Nguyen HO, Posthumus IJ, Wilcox GL: alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther. 2002 Jan;300(1):282-90. [PubMed:11752127 ]
  2. Scheibner J, Trendelenburg AU, Hein L, Starke K, Blandizzi C: Alpha 2-adrenoceptors in the enteric nervous system: a study in alpha 2A-adrenoceptor-deficient mice. Br J Pharmacol. 2002 Feb;135(3):697-704. [PubMed:11834617 ]
  3. Davies MF, Tsui J, Flannery JA, Li X, DeLorey TM, Hoffman BB: Activation of alpha2 adrenergic receptors suppresses fear conditioning: expression of c-Fos and phosphorylated CREB in mouse amygdala. Neuropsychopharmacology. 2004 Feb;29(2):229-39. [PubMed:14583739 ]
  4. Dawson C, Ma D, Chow A, Maze M: Dexmedetomidine enhances analgesic action of nitrous oxide: mechanisms of action. Anesthesiology. 2004 Apr;100(4):894-904. [PubMed:15087625 ]
  5. Ozdogan UK, Lahdesmaki J, Hakala K, Scheinin M: The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol. 2004 Aug 23;497(2):161-71. [PubMed:15306201 ]
  6. Menon DV, Wang Z, Fadel PJ, Arbique D, Leonard D, Li JL, Victor RG, Vongpatanasin W: Central sympatholysis as a novel countermeasure for cocaine-induced sympathetic activation and vasoconstriction in humans. J Am Coll Cardiol. 2007 Aug 14;50(7):626-33. Epub 2007 Jul 30. [PubMed:17692748 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Avsaroglu H, Bull S, Maas-Bakker RF, Scherpenisse P, Van Lith HA, Bergwerff AA, Hellebrekers LJ, Van Zutphen LF, Fink-Gremmels J: Differences in hepatic cytochrome P450 activity correlate with the strain-specific biotransformation of medetomidine in AX/JU and IIIVO/JU inbred rabbits. J Vet Pharmacol Ther. 2008 Aug;31(4):368-77. doi: 10.1111/j.1365-2885.2008.00969.x. [PubMed:18638298 ]
  2. Duhamel MC, Troncy E, Beaudry F: Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. Biomed Chromatogr. 2010 Aug;24(8):868-77. doi: 10.1002/bmc.1379. [PubMed:20020418 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Konstandi M, Lang MA, Kostakis D, Johnson EO, Marselos M: Predominant role of peripheral catecholamines in the stress-induced modulation of CYP1A2 inducibility by benzo(alpha)pyrene. Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):35-44. Epub 2007 Oct 31. [PubMed:17973897 ]
  2. Konstandi M, Kostakis D, Harkitis P, Johnson EO, Marselos M, Adamidis K, Lang MA: Benzo(alpha)pyrene-induced up-regulation of CYP1A2 gene expression: role of adrenoceptor-linked signaling pathways. Life Sci. 2006 Jun 20;79(4):331-41. Epub 2006 Feb 28. [PubMed:16510159 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Konstandi M, Kostakis D, Harkitis P, Marselos M, Johnson EO, Adamidis K, Lang MA: Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol. 2005 Jan 15;69(2):277-87. [PubMed:15627480 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Rodrigues AD, Roberts EM: The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). Drug Metab Dispos. 1997 May;25(5):651-5. [PubMed:9152607 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 03:58